Please login to the form below

Not currently logged in
Email:
Password:

Glybera

This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.

Bluebird puts €1.57m price on gene therapy Zynteglo

Bluebird puts €1.57m price on gene therapy Zynteglo

Zynteglo won't be the first ever 1m plus gene therapy launched in Europe - that distinction went to UniQure's rare disease treatment Glybera, which was launched in 2012.

Latest news

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    Three others (ChondroCelect, PROVENGE and Glybera) were withdrawn, partly due to challenges associated with reimbursement.

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Gene therapy failures. The industry and Europe’s healthcare systems are wary of that magic one million threshold, thanks to the failure of the first ever gene therapy, UniQure’s Glybera.

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... That means gene products hitting that Glybera

  • Health on instalment Health on instalment

    Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Solaris Health looks at the gene therapy revolution Solaris Health looks at the gene therapy revolution

    There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...